Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963\, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849\, A KRAS G12C Selective Inhibitor

INGELHEIM\, Germany and SAN DIEGO\, Sept. 17\, 2020 /PRNewswire/ -- Boehringer Ingelheim and Mirati Therapeutics\, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963\, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation type\, and...